Stock Traders Buy Large Volume of Novavax Call Options (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 25,185 call options on the company. This is an increase of 6% compared to the typical volume of 23,679 call options.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NVAX shares. JPMorgan Chase & Co. increased their price objective on shares of Novavax from $8.00 to $9.00 and gave the stock an "underweight" rating in a research report on Monday, August 12th. B. Riley restated a "buy" rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, Jefferies Financial Group lowered their price target on Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Novavax currently has a consensus rating of "Hold" and an average target price of $17.83.

Novavax Trading Up 1.1 %

Shares of Novavax stock traded up $0.10 during trading hours on Monday, hitting $9.01. 14,624,028 shares of the company were exchanged, compared to its average volume of 9,807,856. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -3.24 and a beta of 2.10. The business has a 50-day moving average of $11.68 and a 200-day moving average of $12.38. Novavax has a 1 year low of $3.53 and a 1 year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.82 by ($0.83). The firm had revenue of $415.50 million for the quarter, compared to analyst estimates of $458.57 million. During the same quarter last year, the business posted $0.58 EPS. The firm's revenue for the quarter was down 2.1% on a year-over-year basis. As a group, research analysts anticipate that Novavax will post -0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novavax

A number of large investors have recently modified their holdings of the business. Swedbank AB acquired a new position in Novavax during the first quarter worth $26,000. Banque Cantonale Vaudoise increased its holdings in shares of Novavax by 500.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 2,500 shares in the last quarter. Herr Investment Group LLC acquired a new stake in shares of Novavax in the first quarter valued at about $48,000. Alpine Global Management LLC purchased a new stake in Novavax during the first quarter worth about $49,000. Finally, Ameritas Investment Partners Inc. grew its position in Novavax by 31.6% during the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 2,711 shares during the period. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.